Viking Therapeutics (VKTX) Stock Forecast & Price Target

$28.87 +0.93 (+3.33%)

As of 04:00 PM Eastern

Viking Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 14 Analyst Ratings

Sell
0

Hold
2

Buy
12

Based on 14 Wall Street analysts who have issued ratings for Viking Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 14 analysts, 2 have given a hold rating, 10 have given a buy rating, and 2 have given a strong buy rating for VKTX.

Consensus Price Target

$87.15
201.88% Upside

According to the 14 analysts' twelve-month price targets for Viking Therapeutics, the average price target is $87.15. The highest price target for VKTX is $138.00, while the lowest price target for VKTX is $30.00. The average price target represents a forecasted upside of 201.88% from the current price of $28.87.

Get the Latest News and Ratings for VKTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Viking Therapeutics and its competitors.

VKTX Analyst Ratings Over Time

Type	Current Forecast 4/30/24 to 4/30/25	1 Month Ago 3/31/24 to 3/31/25	3 Months Ago 1/31/24 to 1/30/25	1 Year Ago 5/1/23 to 4/30/24
Strong Buy	2 Strong Buy rating(s)	1 Strong Buy rating(s)	2 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	10 Buy rating(s)	10 Buy rating(s)	11 Buy rating(s)	10 Buy rating(s)
Hold	2 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$87.15	$95.18	$106.75	$112.25
Forecasted Upside	201.88% Upside	294.13% Upside	216.86% Upside	41.05% Upside
Consensus Rating	Buy	Buy	Buy	Buy

VKTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

VKTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Viking Therapeutics Stock vs. The Competition

Type	Viking Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.82	2.54
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	215.67% Upside	3,089.28% Upside	20.03% Upside
News Sentiment Rating	Neutral News See Recent VKTX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
4/29/2025	Cantor Fitzgerald 3 of 5 stars	S. Seedhouse Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	Truist Financial 2 of 5 stars	Joon Lee Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$95.00 ➝ $75.00	+193.69%
4/24/2025	Morgan Stanley 3 of 5 stars	Michael Ulz Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$105.00 ➝ $102.00	+299.76%
4/24/2025	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Joseph Pantginis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$102.00 ➝ $102.00	+294.74%
4/8/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Richard Law Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$30.00	+39.39%
2/13/2025	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	George Farmer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$102.00	+247.89%
2/7/2025	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Naz Rahman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$120.00 ➝ $70.00	+114.99%
2/7/2025	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Mamtani Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$109.00 ➝ $96.00	+193.19%
2/7/2025	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Lebowitz Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$38.00	+20.79%
2/6/2025	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Steven Seedhouse Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Strong-Buy ➝ Strong-Buy	$122.00 ➝ $125.00	+299.64%
Get the Latest News and Ratings for VKTX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Viking Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
2/6/2025	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Amin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$74.00 ➝ $71.00	+111.94%
11/20/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
9/25/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$138.00 ➝ $138.00	+113.42%
9/11/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$80.00	+46.39%
3/26/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$100.00 ➝ $125.00	+47.58%
3/15/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$80.00	+23.36%
3/7/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$110.00	+20.64%
5/30/2023	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Dupuis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 05:59 PM ET.

Should I Buy Viking Therapeutics Stock? VKTX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 30, 2025. Please send any questions or comments about these Viking Therapeutics pros and cons to contact@marketbeat.com.

Viking Therapeutics
Bull Case

Here are some ways that investors could benefit from investing in Viking Therapeutics, Inc.:

The company is advancing its lead drug candidate, VK2809, which is currently in Phase IIb clinical trials for treating non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD), indicating strong potential for market approval and revenue generation.
Viking Therapeutics, Inc. is also developing VK5211, a selective androgen receptor modulator in Phase II trials for patients recovering from hip fracture surgery, which could address a significant unmet medical need.
The stock price of Viking Therapeutics, Inc. is currently positioned attractively for potential growth, reflecting investor interest and market confidence in its clinical pipeline.
The company has a diverse pipeline with multiple candidates, including VK0612 for type 2 diabetes and VK2735, a dual agonist in early trials, which reduces risk by spreading investment across various therapeutic areas.
Insider ownership stands at 4.10%, suggesting that those with intimate knowledge of the company have a vested interest in its success, which can be a positive signal for investors.

Viking Therapeutics
Bear Case

Investors should be bearish about investing in Viking Therapeutics, Inc. for these reasons:

The company is still in the clinical trial phase for its lead products, which means there is inherent risk associated with the uncertainty of trial outcomes and regulatory approvals.
Viking Therapeutics, Inc. operates in a highly competitive biopharmaceutical market, where many companies are also developing treatments for similar conditions, which could impact market share and profitability.
As a clinical-stage company, Viking Therapeutics, Inc. may require significant capital to fund ongoing research and development, which could lead to dilution of shares if additional funding is sought through equity offerings.
The timeline for drug development can be lengthy, and delays in clinical trials or regulatory processes could hinder the company's ability to bring products to market in a timely manner.
Market volatility and economic conditions can affect investor sentiment and stock performance, which may pose risks for those looking to invest in a company still in the development stage.

VKTX Forecast - Frequently Asked Questions

: According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Viking Therapeutics is $87.15, with a high forecast of $138.00 and a low forecast of $30.00.
: 14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last year. There are currently 2 hold ratings, 10 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VKTX shares.
: According to analysts, Viking Therapeutics's stock has a predicted upside of 201.88% based on their 12-month stock forecasts.
: Over the previous 90 days, Viking Therapeutics's stock had 1 upgrade by analysts.
: Viking Therapeutics has been rated by research analysts at B. Riley, Cantor Fitzgerald, Citigroup, HC Wainwright, Maxim Group, Morgan Stanley, Piper Sandler, Raymond James, Scotiabank, The Goldman Sachs Group, and Truist Financial in the past 90 days.
: Analysts like Viking Therapeutics more than other "medical" companies. The consensus rating for Viking Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how VKTX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:VKTX) was last updated on 4/30/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Viking Therapeutics (VKTX) Stock Forecast & Price Target